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ABSTRACT
Multiple Myeloma (MM) is a haematological neoplasm characterised by the 
clonal proliferation of malignant plasma cells in the bone marrow. The success of 
proteasome inhibitors in the treatment of MM has highlighted the importance of 
the ubiquitin proteasome system (UPS) in the pathogenesis of this disease. In this 
study, we analysed gene expression of UPS components to identify novel therapeutic 
targets within this pathway in MM. Here we demonstrate how this approach identified 
previously validated and novel therapeutic targets. In addition we show that FZR1 
(Fzr), a cofactor of the multi-subunit E3 ligase complex anaphase-promoting complex/
cyclosome (APC/C), represents a novel therapeutic target in myeloma. The APC/C 
associates independently with two cofactors, Fzr and Cdc20, to control cell cycle 
progression. We found high levels of FZR1 in MM primary cells and cell lines and 
demonstrate that expression is further increased on adhesion to bone marrow stromal 
cells (BMSCs). Specific knockdown of either FZR1 or CDC20 reduced viability and 
induced growth arrest of MM cell lines, and resulted in accumulation of APC/CFzr 
substrate Topoisomerase IIα (TOPIIα) or APC/CCdc20 substrate Cyclin B. Similar effects 
were observed following treatment with proTAME, an inhibitor of both APC/CFzr and 
APC/CCdc20. Combinations of proTAME with topoisomerase inhibitors, etoposide and 
doxorubicin, significantly increased cell death in MM cell lines and primary cells, 
particularly if TOPIIα levels were first increased through pre-treatment with proTAME. 
Similarly, combinations of proTAME with the microtubule inhibitor vincristine resulted 
in enhanced cell death. This study demonstrates the potential of targeting the APC/C 
and its cofactors as a therapeutic approach in MM.
INTRODUCTION
Multiple Myeloma (MM) is a haematological 
neoplasm characterised by the clonal proliferation of 
malignant plasma cells in the bone marrow. Over the 
past decade, the introduction of new treatment strategies 
and novel agents such as proteasome inhibitors (PIs) and 
immuno-modulatory drugs (IMiDs), has significantly 
improved the clinical management of MM and extended 
overall survival [1, 2]. One of the most important 
therapeutic advances for MM has been the use of PIs 
to disrupt the ubiquitin proteasome system (UPS). 
Bortezomib, the first-in-class PI, is now a widely used 
component of MM therapy and a second generation PI, 
carfilzomib, was recently approved for the treatment of 
relapsed and refractory MM [3]. Despite the value of PIs 
to MM therapy, not all patients respond and acquired drug 
resistance [4] or dose-limiting side effects can limit their 
clinical utility [5]. This highlights the need to gain a better 
understanding of the molecular mechanisms of MM in 
order to develop additional treatment strategies.
The ubiquitin proteasome system (UPS) plays a 
central role in cellular protein homeostasis through the 
targeted destruction of damaged or mis-folded proteins 
and regulatory proteins that control many critical cellular 
processes. Protein degradation through this pathway 
occurs via two distinct and successive steps: ubiquitination 
of a target protein and subsequent degradation through 
the 26S proteasome. Target proteins are recruited for 
degradation through an enzymatic cascade involving 
three types of enzymes. An E1 (ubiquitin activating 
enzyme) activates ubiquitin and connects it to an E2 
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(ubiquitin conjugating enzyme); an E3 (ubiquitin ligase) 
then mediates the transfer of the activated ubiquitin to 
the target protein, thereby providing substrate specificity. 
The process can also be reversed by a group of proteases 
known as de-ubiquitinating enzymes (DUBs). Altered 
regulation of UPS components has been associated with 
transformation and tumorigenesis and therapeutic targeting 
of this pathway therefore holds great promise [6].
The success of PIs highlights the importance of 
the UPS in MM and it is becoming apparent that there 
are additional targets for therapeutic intervention in this 
pathway. E3 ligases and DUBs, in particular, present 
ideal therapeutic candidates as they may enable targeting 
of an aberrant protein or signalling pathway. Support for 
the potential of inhibiting these enzymes in MM comes 
from a number of studies. The first specific E3 ligase to 
be investigated as a therapeutic candidate was MDM2, an 
E3 ligase for the tumour suppressor p53. Small molecule 
inhibitors of MDM2, have been demonstrated to stabilize 
p53 and its substrates, resulting in apoptosis and cell 
cycle arrest in MM cell lines and primary cells [7, 8]. 
Small molecule inhibitors of the DUBs USP7, USP14 
and UCHL5 have shown significant anti-MM activity, 
including in cells resistant to bortezomib [9, 10]. Indirect 
inhibition of a subset of E3 ligases known as cullin-
RING E3 ligases (CRLs) using the NEDD8-activating 
enzyme (NAE) inhibitor MLN4924 has demonstrated 
encouraging activity in pre-clinical models of MM and 
recently completed a Phase 1 trial for patients with MM 
and lymphoma [11, 12]. Furthermore, IMiDs such as 
Thalidomide, have now been demonstrated to function, 
at least in part, by altering the activity of an E3 ligase 
complex [13].
We analysed gene expression of UPS components 
to identify novel therapeutic targets within this pathway 
in MM. This approach confirmed previously validated 
therapeutic targets and identified novel potential 
therapeutic targets. In this study, we show that FZR1, 
encoding for the protein fizzy-related protein homologue 
(Fzr, also known as Cdh1) represents a novel therapeutic 
target in MM. FZR1 is a cofactor of the multi-subunit E3 
ligase complex anaphase-promoting complex/cyclosome 
(APC/C). The APC/C regulates cell proliferation by 
targeting multiple cell cycle regulators for ubiquitin-
dependent degradation. Its activity depends on interaction 
with two main cofactors, Fzr and Cdc20, which interact 
transiently with the APC/C and select appropriate target 
proteins for ubiquitination. Cdc20 activates the APC/C 
during early mitosis while Fzr associates with the APC/C 
during late mitosis and promotes G1/S transition [14]. 
Chemical inhibition of the APC/C has been proposed as 
a therapeutic strategy in cancer [15–18] and has recently 
been reported to be an attractive potential therapy for 
MM [19]. The majority of these studies have explored 
the effects of APC/C inhibition on inhibiting APC/CCdc20, 
while the role of APC/CFzr in tumorigenesis remains 
controversial. APC/CFzr has been reported as a tumour 
suppressor [20], however, two recent reports propose 
that altering levels of Fzr substrates through inhibition 
of the APC/C may also have therapeutic use. Eguren 
and colleagues identified topoisomerase IIα (TopIIα) 
as a protein substrate of Fzr and demonstrated that both 
knockdown of Fzr and inhibition of the APC/C with the 
inhibitor proTAME, significantly enhance sensitivity 
of tumour cells to TopIIα inhibitors [21]. Furthermore, 
inactivation of Fzr has been shown to result in replicative 
stress, cell cycle arrest and cell death, suggesting that 
APC/CFzr as well as APC/CCdc20 are valid targets for anti-
cancer therapy [22]. The aim of this study was to elucidate 
the importance and therapeutic potential of targeting APC/
CFzr in MM.
RESULTS
Ubiquitin proteasome system gene expression 
signature in Multiple Myeloma
To identify a gene expression signature of UPS 
components in MM we initially performed topic-defined 
microarray analysis of 1286 UPS-related genes in U266 
and OPM-2 cell lines compared to normal bone marrow 
(NBM) mononuclear cells (data available under GEO 
accession number GSE78884). Genes showing a ≥ 1.3-
fold difference and a p-value of ≤ 0.05 were considered 
to be differentially expressed in the MM cell lines 
compared to NBM. Based on these criteria, there were 
131 upregulated genes in OPM-2 and 173 upregulated 
genes in U266 cell lines, with an overlap of 75 genes; 
and 104 and 168 downregulated genes, respectively, with 
an overlap of 58 genes (Supplementary Figure S1A). 
Differentially expressed genes from our dataset were 
subsequently analyzed in 2 published datasets [23, 24] 
(GSE6691, GSE6477) to compare expression in CD138 
selected cells from MM patients with CD138 selected cells 
from NBM; 47 genes showing a ≥ 2-fold difference and a 
p-value of ≤ 0.05 were selected for qPCR validation. Gene 
ontology analysis characterized this UPS gene set into 5 
main subgroups; ubiquitination enzymes, deubiquitinating 
enzymes, proteasomal subunits, heat shock proteins and 
immune response-related. cDNA isolated from CD138 
selected cells from NBM samples (n=3) and newly 
diagnosed and untreated MM patient samples (n=5), and 
from 4 MM cell lines (U266, OPM-2, KMS-18, JJN3) was 
analyzed on custom Taqman Low Density Arrays (TLDA) 
for the 47 genes. In general, there was good correlation 
with differentially expressed genes in TLDA arrays 
compared to the PIQOR array (r = 0.64; Supplementary 
Figure S1B) and 20 of the 47 genes were validated to 
have ≥ 2-fold change in expression across MM patient 
samples and cell lines when compared to normal CD138+ 
cells (Supplementary Figure S1C). Genes that were 
significantly increased in MM patient samples and cell 
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lines versus normal CD138+ cells were found across all 
subgroups: ubiquitination enzymes (n=6), deubiquitination 
enzymes (n=2), proteasomal subunits (n=2), heat shock 
proteins (n=4) and immune response-related genes (n=2). 
Among these dysregulated genes there are a number that 
have already proven successful in pre-clinical and clinical 
investigations for MM therapy (Table 1). We have focused 
in this study on investigating the importance of FZR1, a 
cofactor of the APC/C E3 ligase complex, in MM.
FZR1 is overexpressed in MM
FZR1 mRNA expression was identified to be 
significantly higher (p ≤ 0.03) in U266 and OPM-2 cells 
compared to NBM in our data set (Figure 1A). Similarly, 
FZR1 expression was found to be significantly higher in 
CD138+ cells from MM patients compared to CD138+ 
cells from NBM in 2 independent patient datasets. 
Analysis of data from GSE6691 (Figure 1B) demonstrated 
increased expression in newly diagnosed MM patients 
(n=12; p = 0.01), while analysis of data from GSE6647 
(Figure 1C) demonstrated a significant increase in FZR1 
expression across 4 different stages of plasma cell 
dyscrasias - monoclonal gammopathy of undetermined 
significance (MGUS; n=22; p = 0.009), smoldering 
MM (n=24; p = 0.004), newly diagnosed MM (n=72; p 
= 0.02) and relapsed MM (n=27; p = 0.02). Analysis of 
publically available dataset GSE19784 [25] revealed that 
there was no significant difference in FZR1 expression 
across molecular subgroups of MM (Supplementary 
Figure S2A). Overexpression of FZR1 at the gene level 
was validated by qPCR analysis of CD138+ cells from 
MM patient samples and MM cell lines versus CD138+ 
cells from NBM (Figure 1D). Furthermore, Western 
blotting analysis using protein extracts from NBM 
CD138+ cells and MM CD138+ cells confirmed higher 
protein expression of Fzr in MM (Figure 1E). Analysis 
of the same datasets for APC/C cofactor CDC20 revealed 
that there was no significant difference in expression in 
MM compared to NBM (Supplementary Figure S2B-
S2D), however, significantly higher CDC20 expression 
was observed across distinct molecular subgroups of MM 
(Supplementary Figure S2E).
Knockdown of both FZR1 and CDC20 results in 
decreased viability and cell cycle arrest in MM 
cell lines
APC/C inhibitor proTAME works by blocking the 
interaction of the APC/C with both Fzr and Cdc20 [33]. 
Therefore before analysis with this compound, we sought 
to first determine the effect of individual knockdown of 
either FZR1 or CDC20 on the growth and survival of 
MM cell lines. Cell lines were transduced with retrovirus 
encoding 2 distinct FZR1 and CDC20 – targeting 
shRNA constructs; cells transduced with a non-targeting 
control (NTC) shRNA were used as a control. Following 
puromycin selection, cells were seeded at a density 
of 3 x 105 cells/ml and viability was evaluated after 48 
hrs. Knockdown of either FZR1 or CDC20 resulted in a 
significant decrease (p ≤ 0.05) in viability of all cell lines 
(Figure 2A) and this was associated with an accumulation 
of cells in G2/M phase of the cell cycle (Figure 2B). 
Knockdown of FZR1 and CDC20 was confirmed at 
the gene (Figure 2C) and protein level (Figure 2D) and 
resulted in an increase in protein levels of APC/CFzr 
substrate TopIIα and APC/CCdc20 substrate Cyclin B.
Inhibition of APC/CFzr and APC/CCdc20 with 
proTAME results in decreased viability and cell 
cycle arrest in MM cell lines
A recent study demonstrating that proTAME 
induced apoptosis and inhibited proliferation of MM 
cells primarily focused on its effects on blocking APC/
CCdc20 activity [19]. In this study we determined the effect 
of proTAME (5, 10, 20 µM) on the viability of MM cell 
lines, cell cycle and on expression of substrates of APC/
CFzr and APC/CCdc20. There was a dose-dependent decrease 
in viability of MM cell lines, with ≥ 35% reduction of 
viability observed following 24 hrs treatment with 10 
µM proTAME (Figure 3A). Similar to knockdown of 
FZR1 or CDC20, we found that treatment with proTAME 
at lower doses (5 & 10 μM) led to an increase of cells 
in G2/M phase of the cell cycle, while a higher dose of 
proTAME (20 µM) led to an increase in the sub G0/G1 
population, indicating induction of apoptosis (Figure 3B). 
An increase in the APC/CFzr substrate TopIIα and APC/
CCdc20 substrate Cyclin B was evident following treatment 
with 10 μM proTAME for 24 hrs. To identify when APC/C 
substrate accumulation was apparent, TopIIα and Cyclin 
B levels were evaluated 4, 8 and 24 hrs after treatment 
with 10 μM proTAME. An increase in both substrates was 
evident following 8 hrs treatment (Figure 3D) and this 
concentration and time-point were taken forward for use 
in combination studies.
APC/C inhibition in combination with mitotic 
inhibitors significantly reduces viability of MM 
cell lines and primary MM cells
Knockdown of FZR1 or inhibition of the APC/C 
with proTAME has been reported to enhance the 
sensitivity of a number of tumour cell lines to the 
topoisomerase II inhibitor etoposide, through an increase 
in APC/CFzr substrate TopIIα [21]. We therefore evaluated 
the effect of proTAME (10 μM) or FZR1 knockdown 
in combination with etoposide (1 µM) and doxorubicin 
(100 nM), a commonly used topoisomerase II inhibitor 
in MM therapy. ProTAME was combined with the 
topoisomerase inhibitors either by adding both drugs 
simultaneously or by first treating cells with proTAME 
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for 8 hrs before adding either etoposide or doxorubicin. 
Simultaneous combination with proTAME resulted in 
significantly reduced cell viability compared to single 
agent alone (Figure 4A & 4D), and similar results were 
replicated when etoposide or doxorubicin were combined 
with FZR1 knockdown (Supplementary Figure S3A & 
S3B). More pronounced effects on cell viability were 
seen if cells were first pre-treated with proTAME. Cell 
cycle analysis demonstrated that etoposide as a single 
agent increased the percentage of cells in G2/M and S 
phase, while doxorubicin led to a significant increase in 
G2/M. Combination of both topoisomerase inhibitors 
with proTAME resulted in an increase in the sub G0/
G1 population (Figure 4B & 4E and Supplementary 
Figure S4A & S4B). Consistent with this Western blot 
analysis demonstrated an increase in cleaved caspase-3, 
indicating induction of apoptosis, when proTAME or 
FZR1 knockdown was combined with either drug. TopIIα 
levels were shown to increase following treatment with 
proTAME or FZR1 knockdown, and this was abrogated 
Figure 1: FZR1 expression levels in MM. A. FZR1 gene expression in normal bone marrow (NBM ; n=4), OPM-2 (n=4) and U266 
(n=3) MM cell lines; GSE78884. B. FZR1 gene expression in CD138+ cells from normal donors (n=5) and MM patients (n=12); data 
from published dataset GSE6477. C. FZR1 expression in CD138+ from normal donors (n=16), monoclonal gammopathy of undetermined 
significance (MGUS; n=22), smoldering MM (n=24), newly diagnosed MM (n=72) and relapsed MM (n=27); data from published dataset 
GSE6691. D. qPCR expression of FZR1 in CD138+ cells from healthy donors (n=3), MM patients (n=5) and 4 MM cell lines (U266, 
OPM-2, KMS-18, JJN3; n=3). E. Western blot analysis of FZR1 expression in CD138+ cells from NBM, MM patients and MM cell lines. 
Densitometry analysis is expressed as relative density corrected to loading control. * p ≤ 0.05, ** p ≤ 0.01 (t-test).
Table 1: UPS-signature genes under pre-clinical or clinical investigation for MM
Gene Function Targeted Therapy Reference
BAG3 Molecular chaperone Cantharidin/norcantharidin 26–28
HSPA8 Heat shock protein 70 Ver-15508PET-16
29
30
PSMB6 Proteasome catalytic subunit β1 Bortezomib
Carfilzomib
31
32
USP7 Deubiquitinase P5091 9
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following treatment with etoposide or doxorubicin 
in combination with proTAME (Figure 4C & 4F and 
Supplementary Figure S3D & S3E).
Microtubule inhibitors indirectly result in 
inhibition of APC/C activity and it has been proposed 
that combination of microtubule inhibitors with an 
APC/C inhibitor may enhance cell death [33]. We 
therefore investigated the combination of proTAME 
or FZR1 knockdown with the microtubule inhibitor 
vincristine in MM cell lines. As above, the drugs were 
combined both simultaneously or first pre-treated with 
proTAME for 8 hrs. The combination of proTAME (10 
μM) or FZR1 knockdown with vincristine (10 µM) 
resulted in significantly reduced viability in 2 out of 4 
cell lines compared to either agent alone, pre-treatment 
with proTAME did not enhance cell death any further 
(Figure 4G and Supplementary Figure S3). Cell cycle 
analysis demonstrated that vincristine as a single agent 
increased the percentage of cells in G2/M and sub G0/
G1 populations. Combination with proTAME led to a 
reduction of cells in G2/M phase but no further increase 
in sub G0/G1 phase (Figure 4H and Supplementary 
Figure S4C). Western blot analysis demonstrated a similar 
increase in cleaved caspase-3 both with vincristine as a 
single agent and in combination with proTAME or FZR1 
knockdown. TopIIα levels, as expected, did not change 
following treatment with vincristine (Figure 4I and 
Supplementary Figure S3F).
Proteasome inhibitors (PIs), immunomodulatory 
agents (IMiDs) and corticosteroids form the backbone of 
many current myeloma treatment schedules, therefore, we 
also investigated the effects of proTAME in combination 
with 10 nM carfilzomib (PI), 20 µM pomalidomide 
(IMiD) or 20 nM dexamethasone (corticosteroid). There 
was limited benefit observed to combining proTAME with 
any of these agents (Supplementary Figure S5).
CD138+ cells were selected from 3 MM patient BM 
aspirates and were treated with proTAME in combination 
Figure 2: Knockdown of FZR1 and CDC20 reduces viability and induces cell cycle arrest. A. MM cell lines were transduced 
with two different shRNA constructs against FZR1 or CDC20, viability of MM cell lines was measured 48 hrs post-puromycin selection. 
Results shown represent the mean of 3 independent experiments and are expressed as a percentage of cells transfected with non-targeting 
control (NTC) shRNA. B. Cell cycle analysis of propidium iodide stained cells 48 hrs post-transduction with shFZR1 or shCDC20. 
Results shown represent the mean of 3 independent experiments. C. q-PCR analysis of FZR1 and CDC20 gene expression in U266 cells 
48 hrs post-transduction. Results shown represent the mean of 3 independent experiments and are expressed as fold-change relative to 
NTC. D. Protein expression of Fzr, Cdc20 and their respective substrates TopIIα and Cyclin B in U266 cells 48 hours post-transduction. 
Densitometry analysis is expressed as a percentage of NTC corrected to loading control. * p ≤ 0.05, ** p ≤ 0.01 (t-test).
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with etoposide, doxorubicin or vincristine using the same 
conditions as before. Figure 4J demonstrates that pre-
treatment with proTAME resulted in a highly significant 
reduction in viability for all three drugs compared to 
single agents, and the simultaneous combination of 
proTAME with doxorubicin and vincristine demonstrated 
a significant benefit in primary cells.
BMSC adhesion results in increased Fzr 
expression
BMSCs are well documented to play an important 
role in the survival of MM cells and contribute to cell 
adhesion - mediated drug resistance. Lwin and colleagues 
previously reported that adhesion of lymphoma cell 
lines to BMSCs causes the cells to enter a protected 
quiescent state, mediated through upregulation of Fzr, 
leading to degradation of APC/CFzr substrate Skp2 and an 
accumulation of p27 [34]. To determine if cell adhesion 
affects Fzr expression in MM, we co-cultured MM cell 
lines with the stromal cell line HS-5 for 24 hrs, detached 
adherent MM cells from stromal cells and analyzed 
protein expression alongside cells grown in suspension. 
Similar to the findings by Lwin and colleagues we found 
an increase in Fzr protein expression in MM cell lines 
that were adhered to HS-5 cells, and a reciprocal decrease 
in Skp2 and increase in p27 expression (Figure 5A). 
As BMSCs can protect against drug cytotoxicity, we 
investigated the effect of proTAME in combination with 
etoposide, doxorubicin or vincristine on MM cells co-
cultured with or without BMSCs derived from 3 individual 
MM patient samples. The combination of proTAME with 
all 3 compounds results in a significant (p ≤ 0.05) decrease 
in viability, even when cultured in the presence of BMSCs 
(Figure 5B–5C).
DISCUSSION
The introduction of novel treatment strategies for 
MM, including the use of PIs bortezomib and carfilzomib 
has led to improved response rates and overall survival and 
highlighted the importance of the UPS in this malignancy. 
However, the majority of MM patients will ultimately 
relapse or develop refractory disease, emphasizing the 
need for the identification of additional therapies. The 
UPS consists of many components, most of which have 
the potential to be pharmacologically targeted. With this 
in mind we sought to generate a gene expression signature 
of UPS-related genes in MM to identify novel potential 
therapeutic targets. Through the use of UPS topic-
defined microarray analysis of MM cell lines, combined 
with interrogation of published MM patient datasets, 
Figure 3: Inhibition of the APC/CFzr and APC/CCdc20 in MM cell lines with proTAME. A. Cell viability of MM cell lines 
48 hrs after treatment with 5, 10 or 20 µM proTAME. Results are representative of 3 independent experiments and are expressed as a 
percentage of vehicle treated control. B. Cell cycle analysis of propidium iodide stained cells 48 hrs after treatment with 5, 10 or 20 µM 
proTAME. Results are representative of 3 independent experiments. C. Western blot analysis of TopIIα and Cyclin B levels in U266 cells 
24 hrs after treatment with 5, 10 or 20 µM proTAME. D. Western blot analysis of TopIIα and Cyclin B levels in U266 cells 4, 8 or 24 hrs 
after treatment with 10 µM proTAME. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (t-test).
Oncotarget70487www.impactjournals.com/oncotarget
we identified 20 UPS-related genes with differential 
expression in MM compared to normal CD138+ plasma 
cells. Four of these genes (BAG3, HSPA8, PSMB6, 
USP7) are targeted by inhibitors already in clinical or pre-
clinical studies for MM, giving confidence to the ability of 
this approach to identify UPS-related therapeutic targets 
in MM. Given the interest in the potential of targeting the 
APC/C in cancer, we selected APC/C cofactor Fzr from 
this signature to bring forward for further investigation in 
this study.
The APC/C is an important E3 ligase complex 
involved primarily in cell cycle regulation and its activity 
is dependent on association with 2 cofactors, Cdc20 and 
Fzr. While Cdc20 is known to target a limited number of 
important mitotic regulators for degradation, Fzr is much 
more promiscuous [21]. APC/CCdc20 plays an essential 
role in the degradation of Cyclin B and securin and thus, 
inhibition of the APC/C by preventing Cdc20-dependent 
mitotic exit has been the main focus of therapeutic 
approaches to targeting the APC/C. To date little has been 
studied on the effect of the associated inhibition of the 
APC/CFzr by APC/C inhibitor proTAME. Indeed it may 
even have been thought of as an undesired side effect, 
based on reports of the tumour suppressor effects of Fzr 
in some tumour types. However, accumulating evidence 
suggests that targeting the APC/CFzr may also be of benefit 
to anti-cancer therapies. Based on our gene expression 
array data combined with 2 published patient datasets, we 
Figure 4: APC/C inhibition enhances the effect of conventional anti-mitotic agents in MM cell lines and primary cells. 
A-C. MM cell lines were treated with 10 µM proTAME, 1µM etoposide (ETO), or a combination of both drugs added simultaneously 
or first pre-treated for 8 hrs with proTAME. D-F. MM cell lines were treated with10 µM proTAME, 100 nM doxorubicin (DOX), or a 
combination of both drugs added simultaneously or first pre-treated for 8 hrs with proTAME. G-I. MM cell lines were treated with10 µM 
proTAME, 10 µM vincristine (VINC), or a combination of both drugs added simultaneously or first pre-treated for 8 hrs with proTAME. 
(A,D,G) Cell viability 48 hrs post-treatment; results shown are the mean of 3 independent experiments and are expressed as a percentage of 
vehicle treated control. (B,E,H) Cell cycle analysis of U266 cells 48 hrs post-treatment. (C,F,I) Western blot analysis of TopIIα and cleaved 
caspase-3 48 hrs post-treatment. J. CD138+ cells from 3 MM patients were treated with 10 µM proTAME, 1 µM ETO, 100 nM DOX or 10 
µM VINC as single agents or a combination of proTAME with each drug added simultaneously or first pre-treated for 8 hrs with proTAME. 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 (one-way ANOVA).
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Figure 5: BMSC adhesion results in increased Fzr expression. A. Fzr, Skp2 and p27 protein expression in U266, KMS-18 and 
JJN3 cells cultured in suspension (S) or adhered (A) to HS-5 stromal cell line. Densitometry analysis is expressed relative to loading 
control. B & C. U266 (B) and JJN3 (C) grown with and without primary BMSCs from 3 different MM patients and treated with 10 µM 
proTAME in combination with 1 µM etoposide (ETO), 100 nM doxorubicin (DOX) or 10 µM vincristine (VINC). Drugs were combined 
either simultaneously or first pre-treated with proTAME for 8 hrs. Proliferation was assessed 48 hrs post-treatment and results are expressed 
as a percentage of vehicle treated control. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (one-way ANOVA).
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found significantly higher FZR1 gene expression in MM 
compared to NBM. This is in agreement with a previous 
study comparing gene expression in plasma cells from a 
MM patient with plasma cells from a genetically identical 
twin, in which up-regulation of FZR1 was identified [35]. 
MM is preceded by pre-malignant conditions, MGUS 
or smoldering myeloma, which progress to malignant 
MM at a rate of 1% and 10% per year, respectively [36]. 
Interrogation of dataset GSE6647 demonstrates that FZR1 
expression is also upregulated in these precursor diseases, 
suggesting that dysregulation of FZR1 expression may 
occur early in the disease. Consistent with Lub and 
colleagues [19], we found that FZR1 expression does not 
appear to be associated with any particular cytogenetic or 
risk group as no difference in expression was observed 
across molecular subtypes of the disease. CDC20 
expression on the other hand did not differ significantly 
in MM compared to NBM in any of the datasets analyzed 
in this study, however, again in agreement with Lub 
and colleagues we did observe higher levels of CDC20 
expression in certain molecular subtypes.
Prior to examining the effect of proTAME on both 
APC/CCdc20 and APC/CFzr in MM, we first looked at the 
effect of genetic knockdown of each cofactor individually. 
Knockdown of either Fzr or Cdc20 resulted in a 
comparable reduction in viability of MM cell lines and a 
G2/M arrest. These results are consistent with a number 
of studies in MM and other cancers that have investigated 
the consequence of Cdc20 knockdown [19, 37, 38]. 
Furthermore, similar effects on the cell cycle and cell 
death have previously been reported following knockdown 
of Fzr [22, 39] supporting the potential of Fzr, as well 
as Cdc20 as a therapeutic target in MM. It was recently 
suggested that proTAME may preferentially inhibit APC/
CCdc20 in MM [19]. In this study, we observed an equal 
accumulation of an APC/CFzr substrate (TopIIα) and an 
APC/CCdc20 substrate (Cyclin B) following proTAME 
treatment, which is in accordance with earlier studies 
demonstrating that proTAME inhibits the interaction of 
both cofactors [33]. A dose-dependent decrease in viability 
was seen with proTAME in the cell lines and consistent 
with our knockdown studies, and previous studies, we 
found that proTAME induced a G2/M arrest leading to an 
increase in apoptosis with higher doses.
Following the identification of TopIIα as a substrate 
of APC/CFzr, Eguren and colleagues found that the 
combination of proTAME (to inhibit Fzr) and etoposide 
(to inhibit TopIIα) displayed a synergistic effect in tumour 
cells [21]. Correspondingly, we found that both proTAME 
and knockdown of FZR1 significantly enhanced the anti-
proliferative effect of two topoisomerase inhibitors in 
MM cell lines and primary cells. We also investigated the 
combination of proTAME with the microtubule inhibitor 
vincristine in MM. Microtubule inhibitors disrupt the 
mitotic spindle, leading to activation of the spindle 
assembly checkpoint (SAC) and inhibition of APC/C. 
Although microtubule inhibitors are an important class 
of anti-tumour agent, the response of tumour cells to 
these agents can be highly variable. Zeng and colleagues, 
postulate that as the SAC does not completely supress 
APC/C activity that the cells rely on continued protein 
synthesis to maintain mitotic arrest [33]. Therefore they 
suggest that combination of proTAME and a microtubule 
inhibitor may lead to sustained mitotic arrest and enhanced 
cell death. Our findings support this theory and show that 
the combined treatment of proTAME or FZR1 knockdown 
with vincristine results in enhanced cell death in MM. 
Although proTAME in combination with a PI, IMiD or 
corticosteroid did not enhance cell death, doxorubicin, 
and to a lesser extent vincristine, are currently used 
in combination with novel therapies for MM [40], 
demonstrating that proTAME can enhance the activity of 
clinically relevant MM therapies.
MM cells reside and proliferate almost exclusively 
in the BM and the BM microenvironment plays a well-
established role in supporting MM cell growth and survival 
[41]. MM cells adhere to BMSCs in the BM resulting in 
the activation of many pathways promoting growth and 
survival of MM cells and protecting cells from drug-
induced apoptosis. Using a mantle cell lymphoma (MCL) 
model, Lwin and colleagues demonstrated that adhesion of 
MCL cells to BMSCs resulted in a reversible growth arrest 
that correlated with a decrease in Skp2 and an increase in 
p27 levels in the MCL cells [34]. Moreover, they found 
that BMSC adhesion upregulated Fzr expression and 
that APC/CFzr was an upstream effector of the Skp2/p27 
signalling pathway. As adhesion to BMSCs has previously 
been found to induce a similar reversible growth arrest in 
MM cells [41, 42], we sought to investigate Fzr levels in 
MM cells upon adhesion to BMSCs. In this study, we show 
a similar upregulation of Fzr in MM cells and associated 
decrease in Skp2 and increase in p27 expression. These 
observations imply that this may be a mechanism by which 
BMSCs help to protect malignant MM cells against drug-
induced apoptosis. In support of this theory, the APC/C 
was recently implicated in cancer cell dormancy and 
protection against drug-induced apoptosis in lung cancer 
cell lines [43]. We furthermore investigated the effect of 
proTAME in combination with etoposide, doxorubicin or 
vincristine in MM cell lines co-cultured with MM patient-
derived BMSCs, which are known to support the survival 
of MM cells to a greater extent than normal BMSCs [44]. 
The combination of proTAME and the conventional anti-
mitotic agents still resulted in a significantly enhanced 
reduction in cell viability in the presence of BMSCs 
suggesting that these combinations could target MM 
cells in the BM microenvironment. Interestingly, Fzr has 
also been shown to regulate osteoblast function through 
modulation of Smurf1 activity and depletion of Fzr has 
been found to induce osteoblast differentiation through 
this pathway [45]. Suppression of osteoblast activity plays 
a key role in bone destruction and disease progression in 
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MM [46]. The success of bortezomib in MM therapy can 
be partially attributed to its ability to promote osteoblast 
differentiation in MM [47] and with this is mind, the 
effects of Fzr on osteoblast function in the MM setting 
warrants investigation.
In summary, our studies identified a number of 
UPS components with dysregulated expression in MM, 
some of which have been previously validated. We have 
demonstrated that the APC/C cofactor Fzr is highly 
expressed in MM and expression increases further on 
adhesion to BMSCs. While many studies to date focus 
on blocking the activity of APC/CCdc20 as an anti-cancer 
strategy, we show that APC/CFzr also represents an 
attractive potential therapeutic target in MM. Furthermore, 
the combination of APC/CFzr and APC/CCdc20 inhibition 
with clinically relevant anti-mitotic agents results in 
enhanced anti-MM activity, even in the presence of 
BMSCs. The APC/C represents a promising candidate for 
further preclinical investigation in MM.
MATERIALS AND METHODS
Reagents
ProTAME was purchased from Boston Biochem 
(Cambridge, MA) as a 20 mM stock solution in DMSO, 
stored at -20°C and diluted in RPMI 1640 (Fisher 
Scientific, Loughborough, UK) immediately before use. 
Etoposide, doxorubicin and vincristine were purchased 
from Cayman Chemical (Cambridge, UK), reconstituted 
in DMSO and stored at -20°C.
Cell lines
U266, OPM-2, KMS-18, JJN3, HS-5 and Phoenix 
GP cells were cultured in a humidified incubator at 37°C 
and 5% CO2 in RPMI 1640 medium supplemented with 
10% fetal bovine serum and 100 U/mL penicillin, 100 µg/
mL streptomycin (Fisher Scientific, Loughborough, UK). 
Authentication using short tandem repeat profiling (STR) 
was conducted by LGC Standards Cell Line Authentication 
Service within 1 year of use for these experiments.
Primary samples
Bone marrow samples from MM patients were 
obtained with ethical approval from the Northern Ireland 
Biobank (approval # NIB12-0061) and those involved gave 
their informed consent in accordance with the Declaration 
of Helsinki. Human bone marrow mononuclear cells were 
purchased from Stem Cell Technologies (Cambridge, 
UK) for use as a normal control. CD138 expression is 
a hallmark of plasma cells and multiple myeloma cells. 
CD138+ cells were enriched from primary samples using 
the AutoMACS system (Miltenyi Biotech, Germany) 
according to the manufacturer’s instructions.
PIQOR ubiquitin-proteasome pathway gene 
expression array
Topic defined PIQOR (Parallel Identification and 
Quantification Of RNAs) Microarrays (Miltenyi Biotech, 
Germany) comprising 1286 UPS-associated genes were used 
to generate gene expression profiles of normal bone marrow 
(NBM) versus MM cell lines. mRNA was isolated from 
NBM (n=5) and MM cell lines [U266 (n=3) and OPM-2 
(n=5)] and cDNA synthesized using the μMACS™ One-step 
T7 Template Kit according to the manufacturer’s instructions 
(Miltenyi Biotech, Germany). Cy3-labelled samples of 
interest were hybridized against a Cy5-labelled common 
reference according to the manufacturer’s instructions 
(Miltenyi Biotech, Germany). Microarray slides were 
scanned with an Axon GenePix 4400A microarray scanner 
(MDS analytical technologies) and fluorescence intensity 
data were measured by GenePix Pro 7.0. Raw data was 
background corrected (normexp), normalized within each 
array with a modification of the LOWESS method (print-
tip loess normalization) and between all arrays (quantile 
normalization) with the R/Bioconductor package Limma. 
The medians of the log2 normalized intensities for each array, 
or the log2-ratios relative to the co-hybridized reference 
RNA were subsequently calculated for each probe set from 
the four replicate values. For statistical group comparisons 
between OPM or U266 cells and NBM cells, a two-sided 
t-test with equal variance was used (R/Bioconductor) using 
the normalized log2-ratio data.
Taqman low-density array
Total RNA was isolated from cells using Trizol 
(Life Technogies, Paisley, UK), and converted to cDNA 
using MMLV (Life Technologies Paisley, UK) according 
to the manufacturer’s instructions. Custom TaqMan® 
Array plates were designed to validate gene expression 
arrays of 48 UPS associated genes. Cycling conditions 
were as follows; 40 cycles of 95°C for 15 sec, followed 
by 60°C for 1 min. Each array was analysed on the 
7900 system using Taqman Low Density Array (TLDA) 
default thermal-cycling conditions and 18S used as the 
endogenous control (Applied Biosystems, Paisley, UK).
Retroviral transfection
Retroviruses expressing an shRNA against FZR1 and 
CDC20 were generated by transfection of a pRSC vector 
together with pMD2.G into Phoenix GP cells. shRNA 
sequences are shown below. Cells infected with vector 
expressing non-targeting control (NTC) shRNA were used 
as controls. Cells were selected in 0.5 µg/ml puromycin 
(Sigma-Aldrich, Dorset, UK), 48 hrs post-transduction.
shFZR1 1 CCCGTTCGACAAAGGTAAA
shFZR1 2 TGAGAACACGATGCCACGC
shCDC20 1 CGGCTTCGAAATATGACCA
shCDC20 2 GGTTCAGACCACTCCTAGC
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Cell viability
Cell Titer-Glo® luminescent assay (Promega, 
Southampton, UK) was used to analyze cell viability by 
measuring ATP levels according to the manufacturer’s 
instructions. Luminescence was measured using a Tecan 
Genios microplate reader.
Bone marrow stromal cell (BMSC) culture and 
MM co-culture assay
BM aspirates from MM patients were subjected to 
mononuclear cell separation by Ficoll-Hipaque density 
sedimentation, CD138 depleted and cultured in vitro for 
at least 3 weeks to establish long-term BMSC cultures. 
The adherent cell monolayer was harvested in HBSS 
containing 0.25% trypsin and 0.02% EDTA (Fisher 
Scientific, Loughborough, UK), washed, and collected 
by centrifugation. MM cell lines or MM patient-BMSCs 
were cultured either alone or together at 1:5 (BMSC/MM) 
ratio for 48 hrs, and cell proliferation was measured using 
the non-radioactive WST-1 colorimetric assay, as per 
manufacturers’ instructions (Roche, Sussex, UK).
Cell cycle analysis
Cells were harvested, washed in phosphate-buffered 
saline and fixed in 70% ethanol. Fixed cells were stained 
with 50 μg/ml propidium iodide solution containing 0.25 
mg/ml RNase. DNA content was measured with an LSRII 
flow cytometer and subpopulations were identified using 
FACS Diva and Flowing Software (Turku Centre for 
Biotechnology, Finland).
Western blotting
Cells were harvested and lysed in radioimmuno 
precipitation assay buffer containing protease and 
phosphatase inhibitors. Equal amounts of protein were 
denatured in LDS sample buffer (Invitrogen Ltd, Paisley, 
UK) at 95°C for 5 minutes, resolved by SDS-PAGE on 10% 
Bis-Tris gels (Invitrogen Ltd, Paisley, UK) and subsequently 
transferred to a polyvinylidene fluoride membrane. 
Immunoblotting was carried out using antibodies against 
FZR1, Topoisomerase II α, GAPDH (Abcam, Cambridge, 
UK), Pan-Actin, Cyclin B, Cleaved Caspase-3, SKP2, p27 
(Cell Signaling Technology, Hertfordshire, UK) and CDC20 
(Santa Cruz, Heidelberg, Germany) and secondary antibodies 
anti-mouse and anti-rabbit (DAKO, Cambridgeshire, UK). 
Blots were scanned into the AutoChemi System (UVP, 
Cambridge, UK) and analysed using LabWorks 4.5 image 
acquisition and analysis software.
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